Breaking News

You are here » Indian-Commodity  :  Commodities  :  Crude Oil  :  Crude palm oil futures trade lower on high arrivals

09-Aug2018

Crude palm oil futures trade lower on high arrivals

Crude palm oil futures traded lower on MCX, with the liquidation of bets by market players amid high arrivals from growing regions. Moreover, sluggish demand from domestic markets also weighed on the CPO future prices.

The contract for August delivery was trading at Rs 593.50, down by 0.27% or Rs 1.60 from its previous closing of Rs 595.10. The open interest of the contract stood at 7048 lots.

The contract for September delivery was trading at Rs 592.20, down by 0.32% or Rs 1.90 from its previous closing of Rs 594.10. The open interest of the contract stood at 5591 lots on MCX.


Related News

View all news

Crude oil futures end higher on Friday

Crude oil futures ended higher on Friday on worries about possible impact of US sanctions on Iran's oil exports on crude supply in the market coupled with potential US-Saudi tensions. Prices also supported......

Crude oil futures extend losses on Thursday

Extending previous session losses, crude oil futures ended lower on Thursday due to a sharp jump in US crude inventories last week and on demand growth concerns. The Energy Information Administration's......

Crude oil futures trade lower on MCX

Crude oil futures traded lower on MCX, as speculators reduced their bets due to trade war concerns combined with surging US oil stockpiles reported on Thursday. Though, signs of surging demand in China,......

Top News

View all news

Bhansali Engineering Polymers reports 33% fall in Q2 net profit

Bhansali Engineering Polymers has reported results for second quarter ended September 30, 2018.The company has reported 32.71% fall in its net profit at Rs 16.89 crore for the quarter under review as compared......

Biocon, Mylan N.V. receive positive CHMP opinion for Ogivri

Biocon and Mylan N.V. have announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of Ogivri, a biosimilar......

Lupin Neurosciences receives positive CHMP opinion for NaMuscla

Lupin Neurosciences, a specialty pharma division of Lupin has announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA),......